Compare Abeona Therapeutics Inc (ABEO) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Fidelity National Information Servcs Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Fidelity National Information Servcs Inc trades at $40.84 (market cap $22.02B). The key difference: Fidelity National Information Servcs Inc is far larger — about 59× Abeona Therapeutics Inc's market cap, and Fidelity National Information Servcs Inc pays a 3.94% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FIS | |
|---|---|---|
Market Cap | $373.32M | $22.02B |
Sector | Health | Technology |
52-Week High | $7.23 | $81.94 |
52-Week Low | $4.17 | $37.72 |
Enterprise Value | $228.22M | $42.41B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FIS trades at $42.6, up 1.91% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with 2025 revenue of $10.68B and a net income margin of 23.35%, supported by a low P/E of 8. Recent news highlights strategic wins, including partnerships with Frankfurt International Bank and First Commerce Bank for cloud-native banking solutions, reinforcing its competitive positioning in financial technology.
The outlook is positive with a consensus price target of $55.40, implying significant upside. Key opportunities include continued revenue growth and margin expansion, but risks involve a high debt load and macroeconomic pressures on lending markets. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on debt management and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
